

SPECIAL EDITORIAL REVIEW

APLAR rheumatoid arthritis treatment recommendations

Chak Sing LAU,¹ Faith CHIA,² Andrew HARRISON,³ Tsu-Yi HSIEH,⁴ Rahul JAIN,⁵ Seung Min JUNG,⁶ Mitsumasa KISHIMOTO,⁷ Ashok KUMAR,⁸ Khai Pang LEONG,² Zhanguo LI,⁹ Juan Javier LICHAUCO,¹⁰ Worawit LOUTHRENOO,¹¹ Shue-Fen LUO,¹² Peter NASH,¹³ Chin Teck NG,¹⁴ Sung-Hwan PARK,⁶ Bagus Putu Putra SURYANA,¹⁵ Parawee SUWANNALAI,¹⁶ Linda Kurniaty WIJAYA,¹⁷ Kazuhiko YAMAMOTO,¹⁸ Yue YANG⁹ and Swan Sim YEAP¹⁹

¹Division of Rheumatology and Clinical Immunology, Queen Mary Hospital, University of Hong Kong, Hong Kong, ²Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore City, Singapore, ³Department of Medicine, University of Otago Wellington, Wellington South, New Zealand, ⁴Section of Allergy, Immunology and Rheumatology, and Section of Clinical Skills Training, Taichung Veterans General Hospital, Taichung, Taiwan, ⁵Narayana Hospital, Jaipur, India, ⁶Division of Rheumatology, Department of Internal Medicine, The Catholic University of Korea, St. Mary's Hospital, Seoul, South Korea, ⁷Immuno-Rheumatology Center, St Luke's International Hospital, Tokyo, Japan, ⁸Department of Rheumatology, Fortis Flt. Lt Rajan Dhall Hospital, New Delhi, India, ⁹Department of Rheumatology, Peking University People's Hospital, Beijing, China, ¹⁰St. Luke's Medical Center, Quezon City, Philippines, ¹¹Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, ¹²Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital and Chang Gung University, Tao-Yuan, Taiwan, ¹³Department of Medicine, University of Queensland, Brisbane, Queensland, Australia, ¹⁴Department of Rheumatology and Immunology, Singapore General Hospital, Singapore City, Singapore, ¹⁵Rheumatology Division, Department of Internal Medicine, Brawijaya University, Saiful Anwar General Hospital, Malang, Indonesia, ¹⁶Allergy, Immunology and Rheumatology Division, Internal Medicine Department, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, ¹⁷Division of Rheumatology, Department of Internal Medicine, University of Indonesia, Jakarta, Indonesia, ¹⁸Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, and ¹⁹Subang Jaya Medical Centre, Selangor, Malaysia

Abstract

Aims: Rheumatoid arthritis is a chronic inflammatory condition that affects approximately 1% of the world's population. There are a wide number of guidelines and recommendations available to support the treatment of rheumatoid arthritis; however, the evidence used for these guidelines is predominantly based on studies in Caucasian subjects and may not be relevant for rheumatoid arthritis patients in the Asia-Pacific region. Therefore, the Asia Pacific League of Associations for Rheumatology established a Steering Committee in 2013 to address this issue.

Materials and methods: The AGREE II instrument and the ADAPTE Collaboration framework were applied to systematically identify, appraise, synthesize, and adapt international rheumatoid arthritis guidelines for use in the Asia-Pacific region.

Results: Forty rheumatoid arthritis treatment recommendations, based on evidence and expert opinion, were drafted and are presented in this report.

Correspondence: Professor Chak Sing Lau, Division of Rheumatology and Clinical Immunology, Queen Mary Hospital, University of Hong Kong, Hong Kong, Hong Kong.
Email: cslau@hku.hk

Conclusion: The Asia Pacific of Associations for Rheumatology rheumatoid arthritis treatment recommendations are intended to serve as a reference for best practice management of rheumatoid arthritis in Asia-Pacific, focusing on local issues to ensure the delivery of basic care for these patients, and to improve their outcomes. In addition, the document will serve as a reference for national rheumatology associations in Asia-Pacific for developing guidelines in their respective countries.

Key words: drug treatment, rheumatoid arthritis.

INTRODUCTION

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease of unknown etiology that affects approximately 1% of the global population.^{1–3} The disease is characterized by inflammation, pain, stiffness and progressive joint destruction leading to high rates of morbidity and mortality in the affected individuals.^{1–3} Furthermore, RA is associated with productivity losses and increased financial burden, increased psychological distress, depression and, consequently, significantly decreased health-related quality of life.^{4–6}

Disease-modifying antirheumatic drugs (DMARDs) form the cornerstone of RA treatment. These agents have the capacity to modify the disease process by reducing or reversing signs and symptoms, disability, impairment of quality of life, inability to work, and progression of joint damage.⁷ Early and aggressive treatment with DMARDs has been shown to be effective in altering the clinical course of RA, and slowing or stopping the radiographic progression. DMARDs are broadly classified into conventional DMARDs (cDMARDs) including synthetic chemical agents such as methotrexate, sulfasalazine and leflunomide, and biological DMARDs (bDMARDs), including: tumor necrosis factor (TNF) inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab and infliximab); the T-cell costimulation inhibitor, abatacept; the anti-B cell agent, rituximab; the interleukin (IL)-6 receptor (IL-6R)-blocking monoclonal antibody, tocilizumab; as well as the IL-1 inhibitor, anakinra. Recently, tofacitinib, a Janus kinase (JAK) inhibitor, has also been shown to have disease-modifying effects in RA.

NEED FOR RA RECOMMENDATIONS IN THE ASIA-PACIFIC (AP) REGION

As the evidence used in most international RA treatment guidelines is obtained predominantly from studies in Caucasian subjects, these guidelines may not be relevant for RA patients in the AP countries. Data show that there is an increased prevalence of certain infections (e.g., tuberculosis [TB], hepatitis B and C infection,

Epstein–Barr virus infection)^{8,9} and malignancies (e.g., T-cell and natural killer-cell lymphomas,¹⁰ stomach cancer¹¹) in the AP region. Thus, a Steering Committee under the auspice of the Asia Pacific League of Associations for Rheumatology (APLAR) was formed in 2013 to formulate AP region-specific treatment recommendations for RA that address AP-specific issues.

However, the AP region has vast intra-regional diversity in terms of ethnicities, socioeconomic structures and health resources; these characteristics also differ from those in Western countries. Furthermore, the availability and dosage of medications vary across AP countries. Thus, it is difficult to develop RA treatment recommendations that will be appropriate for all AP countries. Owing to a shortage of rheumatologists, RA patients in the region are also often managed by general practitioners and allied health practitioners. Consequently, the treatment practices are not standardized and vary widely, even within countries. Furthermore, there are limited data from the AP region to endorse evidence-based recommendations that may be considered more appropriate in some countries in the region. Nevertheless, this Steering Committee aimed to develop recommendations that will be as evidence-based as possible and define the best practices for managing RA in the AP region.

In addition, the Steering Committee also made recommendations based on expert opinion and consensus so that countries with limited resources may be able to achieve the minimum essential standard of care for their RA patients.

TARGET AUDIENCE AND CONTENTS

The intended target audience for this document includes rheumatologists and all practitioners who manage RA. It focuses predominantly on recommendations for the pharmacological treatment of RA. The document includes 40 recommendations across the following RA treatment domains: general RA treatment strategies; role of non-steroidal anti-inflammatory drugs (NSAIDs), including: cyclooxygenase-2 (COX-2) inhibitors; role of corticosteroids; role of conventional DMARDs

Table 1 Key questions regarding the treatment of RA in the AP region

A. General RA treatment strategies
i. What are the goals of treatment?
ii. What are the clinical, laboratory and radiological features and prognostic features that will guide treatment decisions?
iii. Overall treatment strategies
1. How is treatment initiated and the goal of treatment discussed with patients?
2. How are adjustments made based on clinical, biochemical and radiological findings?
a. What are the response criteria and what should be the frequency of monitoring?
b. What precautions are necessary for ensuring the safety of patients on RA treatment?
3. How long should patients be maintained on DMARD and non-DMARD treatments?
B. Role of NSAIDs including COX-2 inhibitors
i. What is the optimum dosage of NSAIDs and COX-2 inhibitors?
ii. What are the side effects of NSAIDs and COX-2 inhibitors?
iii. What are the associated gastrointestinal and cardiovascular risks?
iv. What are the adverse events in patients with comorbidities?
v. Do NSAIDs have disease-modifying activity?
C. Role of cDMARDs
i. When are cDMARDs prescribed?
ii. Which cDMARDs should be used?
iii. What investigations are required before starting cDMARD treatment?
iv. What is the optimal dosing for cDMARDs?
v. Which cDMARD combinations are preferred?
vi. What are the precautions when using cDMARDs?
vii. How to monitor patients on cDMARDs and what is the frequency of assessment?
viii. How is treatment failure defined with cDMARDs?
ix. Is dose reduction or cessation possible with cDMARDs when disease is deemed to be in remission?
D. Role of corticosteroid agents
i. What is the difference in opinions between AP and European/US practitioners about corticosteroid use?
ii. When should corticosteroids be prescribed?
iii. How should corticosteroids be administered?
iv. What is the optimal dosing regimen for corticosteroids?
v. When should treatment with corticosteroids be tapered and stopped?
vi. What precautions are necessary when treating with corticosteroids?
vii. How should patients on corticosteroids be monitored?

Table 1 (continued)

E. Role of bDMARD agents
i. When should bDMARDs be prescribed?
1. What is the definition of inadequate response to cDMARDs?
2. Which prognostic factors should be assessed when prescribing bDMARDs?
ii. Which class of drugs should be used?
1. Need to discuss individual agents or class?
2. What is the algorithm for initiating and switching treatment with bDMARDs?
iii. Should methotrexate or other cDMARDs be co-prescribed with bDMARDs?
iv. Which investigations should be performed before prescribing bDMARDs?
v. What is the optimal dosing strategy for different bDMARDs?
vi. What is the therapeutic strategy for combination therapy of bDMARDs with non-biologic DMARDs?
vii. What precautions should be taken when prescribing bDMARDs?
viii. How should treatment with bDMARDs be monitored and what should be the frequency of assessment?
ix. What are the definitions of primary and secondary treatment failure with bDMARDs?
x. What is the therapeutic strategy for dose reduction or cessation with bDMARDs when RA is deemed to be in remission?
xi. What is the therapeutic strategy for bDMARDs in the following special situations:
1. Infectious complications
a. TB
b. Hepatitis
c. Others
2. Autoimmunity
3. Malignancies
4. Surgery
5. Pregnancy/lactation
6. Vaccination policies

F. What is the role of complementary/unproven therapies in the treatment of RA?

AP, Asia Pacific; bDMARD, biological DMARD; cDMARD, conventional DMARD; COX-2 inhibitors, cyclooxygenase-2 inhibitors; DMARD, disease-modifying antirheumatic drug; NSAID, non-steroidal anti-inflammatory drug; RA, rheumatoid arthritis; TB, tuberculosis.

(cDMARDs); and role of bDMARD agents. Specific key questions across these key domains were identified and recommendation statements developed accordingly (Table 1).

This document does not include recommendations for the diagnosis of RA, patient referral policies or

management of comorbid conditions. Furthermore, costs were not embedded in the discussion of the recommendations, as formal cost-effectiveness analyses were not performed.

FUNDING AND CONFLICT OF INTEREST

The process of developing the APLAR RA treatment recommendations was funded by APLAR and was also supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie, Janssen, Pfizer, Roche and UCB. Relevant disclosures for the Steering Committee members, including industry funding, consultancies and commercial interests, are included at the end of this article.

OBJECTIVES

The primary objective was to develop a document that would serve as a reference for best RA management practices in the AP region, focusing on local issues in the region. In addition, the document would also serve as a reference for national rheumatology associations in the region for developing RA guidelines in respective countries.

MATERIALS AND METHODS

The ADAPTE framework was used to systematically identify, appraise, synthesize, and adapt international RA guidelines for use in the AP region. This was done by following the steps outlined in the ADAPTE manual and toolkit, and helped to expedite the process of recommendation development.^{12,13}

Assembly of the APLAR RA Recommendations Steering Committee

A Steering Committee was formed by inviting 22 members of APLAR representing 12 countries from the AP region, as well as one RA patient for developing this set of recommendations. The APLAR members were rheumatology experts who had served on numerous RA research projects and decision-making panels both internationally and in their respective countries. All members of the Steering Committee attended the meetings, contributed to discussions and were actively involved in every phase of recommendation development. No representative of pharmaceutical companies was involved in any part of recommendation development.

Scope of the recommendations

Members of the Steering Committee developed key questions pertaining to RA treatment in the AP region. These questions, developed during a face-to-face meeting, addressed various domains of RA treatment, as described earlier (Table 1).

Search criteria

The studies included were clinical practice guidelines and consensus statements with recommendations for adult RA populations, and published in English between January 2000 and December 2013. Studies that provided evidence from the AP region to support recommendation of RA treatment practices specific to the region were also included. Non-English articles were considered, provided a member of the Steering Committee could translate them into English. Articles were excluded if they did not address the key questions or were deemed to be of poor methodological quality by a validated guidelines quality appraisal instrument.^{14,15}

Search strategy

A systematic search was performed according to the inclusion–exclusion criteria described above in Medline, EMBASE, Google Scholar and SCOPUS. The search terms included RA, specific drug names for cDMARDs and bDMARDs, NSAIDs, corticosteroids, AP, guidelines, consensus statements and recommendations. All search results were reviewed by two independent members. The steps involved in the systematic search are shown in Figure 1.

Appraisal of guideline quality

The quality of each guideline was assessed using a validated questionnaire, the Appraisal of Guidelines, Research and Evaluation (AGREE) instrument.¹⁵ This instrument includes 23 questions that are organized into six domains: (i) scope and purpose; (ii) stakeholder involvement; (iii) rigor of development; (iv) clarity of presentation; (v) applicability; and (vi) editorial independence. Each of the 23 items targets various aspects of practice guideline quality. Each guideline was independently assessed by two reviewers to formulate a single-item overall assessment as 'Recommend', 'Recommend with modifications' or 'Not recommend'.

Grading evidence

Each guideline had a different system for grading evidence. To reconcile these differences, we translated each




Figure 1 Steps in the systematic review of international guidelines and recommendations on the pharmacological management of rheumatoid arthritis.

guideline's evidence grading system into a simplified system as suggested by the Scottish Intercollegiate Guideline Network (SIGN) to assign a level of evidence and strength of recommendation for each recommendation.¹⁶

Evidence synthesis

We prepared a table of included guidelines containing descriptive characteristics, including guideline developer, country, year, summary of recommendations and AGREE assessment, for each subsection of the guideline. This was followed by development of evidence tables for each question; these included guideline characteristics, recommendations, summary of guideline assessment (AGREE assessment) and supporting evidence (Table 2).

Development of recommendations

Members of the Steering Committee summarized recommendations and supporting evidence from international guidelines to address each key question. A recommendation for the AP region was developed by adapting and rewording the existing recommendation. An emphasis was placed on recent guidelines with strong methodological quality. Supporting evidence from randomized controlled trials (RCTs) and observational studies referenced by the guideline was reviewed by members in detail. All members partici-

pated in developing the wording of recommendations. Consensus was achieved by using the Delphi technique whereby members had an opportunity to cast a vote anonymously, without getting swayed by opinions of fellow members; disagreements were resolved through discussions and multiple rounds of voting. Statements were included as recommendations provided more than 80% of the members participated in the polling and more than 50% of the members voted in favor of the outcome. Setting the acceptance margin to 70% resulted in exclusion of many questions considered important during meeting discussions. Thus, for the purpose of this recommendation document, a majority was determined by more than 50% of votes.

Extended review

Draft recommendations developed by the group were sent to Josef Smolen and Vibeke Strand for review and comments. The draft recommendations were also presented in an open forum during the 2014 APLAR Congress to seek opinions and suggestions from participants. Feedback from the respondents was used to finalize the recommendations and inform supporting text. This document was developed in accordance with the principles outlined by the AGREE II instrument and the ADAPTE collaboration. The recommendations were also sent for review and official endorsement by APLAR.

Table 2 System used for assigning level of evidence and strength of recommendation¹⁶

Levels of evidence	Strength of recommendation
I. Meta-analyses, systematic reviews of RCTs, or individual RCT	A. Strong recommendation: Direct level I evidence
II. Meta-analyses, systematic reviews of observational studies (cohort/case control studies), or individual observational studies OR RCT subgroup/post-hoc analyses	B. Moderate recommendation: Direct level II evidence or extrapolated level I evidence
III. Non-analytical studies, e.g., case reports, case series	C. Weak recommendation: Direct level III evidence or extrapolated level II evidence
IV. Expert opinion OR Recommendations are not linked to evidence	D. Consensus recommendation: Expert opinion based on very limited evidence

RCT, randomized controlled trial.

RESULTS

Each recommendation is presented with a level of evidence and strength (Table 3) and accompanied with supporting text which is structured as follows.

Supporting evidence

Description of the source guidelines used for adaptation

Summary of evidence linked to recommendation statement

Summary of original evidence presented in source guidelines.

Special comment/recommendation for the AP region

A special comment/expert opinion that is relevant for the region.

Recommendations

A summary of the recommendations is presented in Table 3. It should be noted that the recommendations are stratified into different sections relevant to the different stages and groups of drugs used in the treatment of RA. These sections may thus be referenced separately and individually. An algorithm summarizing the recommendations for treatment of patients with RA in the AP region is presented in Figure 2.

Section 1 – General RA treatment strategies

Recommendation 1. RA treatment should be aimed at maintaining physical functioning and good quality of life through achieving a state of sustained remission, or low disease activity when remission may not be an achievable target. (Level II; Strength B)

Supporting evidence

References 17–29.

Summary of evidence linked to recommendation statement

It was noted that, in every patient, treatment should be aimed at reaching a target of remission^{17–24} or low disease activity,^{17–20,24} as soon as possible²⁵ and measuring disease activity using objective parameters such as Disease Activity Score (DAS), DAS28 (DAS of 28 joints), Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI).^{26,27} Consequently, this will halt joint damage, prevent disability and improve quality of life.^{28,29} It should be noted that DAS28 < 2.6 is regarded by the Food and Drug Administration (FDA) as a cut-off point for low disease activity, whereas remission is probably better defined according to the American College of Rheumatology–European League Against Rheumatism (ACR–EULAR) criteria based on SDAI, CDAI or the Boolean criteria.³⁰

Special comment/recommendation for the AP region

In the AP region, there may be some situations in which remission or even low disease activity may not be possible. For example, many AP patients first present to their clinician with advanced disease and often severe joint deformity. For these patients to achieve remission, the use of bDMARDs is often required but these agents are not affordable for most of these patients. Furthermore, many patients are engaged in work involving physical labor which may aggravate the signs and symptoms of RA, rendering a low disease activity state non-achievable. Thus, for many RA patients in the region, we recommend counselling to ensure compliance, and an agreement on a treatment target, maintaining symptom control and work ability, to be reached between the clinician and the patient.

Recommendation 2. Treatment of RA is a shared decision between the clinician and patient, and should be started once diagnosed. (Level I; Strength A)

Supporting evidence

References 17, 19–25, 27, 29, 31, 32 and 33.

Table 3 APLAR treatment recommendations for the management of RA in the AP region

Recommendations	Level	Strength
Section 1 – General RA treatment strategies		
1. RA treatment should be aimed at maintaining physical functioning and good quality of life through achieving a state of sustained remission, or low disease activity when remission may not be an achievable target.	II	B
2. Treatment of RA is a shared decision between the clinician and patient, and should be started once diagnosed.	I	A
3. The choice of treatment is based on the findings of active disease and/or poor prognosis and comorbidities.	II	B
4. Poor prognostic factors include positivity for ACPA or RF, increased ESR or CRP, radiological evidence of erosion or progression of erosions.	II	B
5. All patients with recently diagnosed RA or active disease should be monitored for disease activity every 1 to 3 months.	I	A
6. A suitable and practical standardized measure of disease activity should be routinely performed to assess patients' response to treatment.	I	A
7. Safety monitoring while patients are on bDMARD therapy is likewise recommended.	II	B
8. All patients should be assessed clinically at presentation for extra-articular disease manifestations, comorbidities, and infections such as TB and hepatitis (II). Information on vaccination status and special situations such as pregnancy and lactation should be obtained (II).	II	B
9. If patients show persistent remission for 6 months, treatment with corticosteroids and NSAIDs may be tapered, with the aim of eventually stopping these treatments.	II	B
10. If a patient is in sustained remission for more than 6 to 12 months after discontinuation of NSAIDs, corticosteroids and bDMARDs, then a gradual reduction in cDMARDs can be attempted with caution, as a shared decision between the patient and physician.	IV	D
Section 2 – Role of NSAIDs (including COX-2 inhibitors)		
11. NSAIDs and COX-2 inhibitors should be used at the lowest effective dose for the shortest possible period of time.	IV	D
Section 3 – Role of corticosteroids		
12. Oral corticosteroid monotherapy is not recommended.	IV	D
13. Oral corticosteroids can be considered to control active RA in combination with cDMARDs.	I	A
14. In early RA, the addition of low-dose corticosteroids (prednisolone \leq 7.5 mg/day) to cDMARDs leads to a reduction in radiographic progression.	I	A
15. Corticosteroids should be used in the lowest possible dose and tapered as rapidly as clinically feasible.	IV	D
Section 4 – Role of conventional DMARDs		
16. Treatment with cDMARDs as monotherapy or in combination should be started as soon as the diagnosis of RA is made.	I	A
17. Methotrexate is the first-line cDMARD for RA patients, and is considered as the "anchor drug".	I	A
18. Patients who cannot tolerate methotrexate may receive other cDMARDs such as leflunomide, sulfasalazine and hydroxychloroquine as first-line treatments. Bucillamine, iguratimod, cyclosporin, azathioprine, IM gold or tacrolimus may also be considered in some AP countries.	I	B
19. Pretreatment investigations: complete blood count, liver function and renal function tests, viral hepatitis serology and chest radiograph should be ordered prior to initiating methotrexate therapy.	II	B
20. Combination cDMARD therapy should be considered in active RA patients, particularly those with poor prognostic factors.	I	B
21. Combination cDMARD therapy should include methotrexate as the anchor drug unless methotrexate is contraindicated.	II	B
22. Triple therapy with cDMARDs is an effective option in patients who show inadequate response to methotrexate monotherapy.	II	B
23. Patients should be assessed every 1 to 3 months after the initial treatment or change of regimen until the disease is stabilized, in remission or in low disease activity state.	I	A
24. Patients who have been stabilized or are in remission or low disease activity can be monitored every 3 to 6 months.	IV	D

Table 3 (continued)

Recommendations	Level	Strength
25. Definition of treatment failure: Inadequate response with cDMARDs is defined as failure to achieve remission or low disease activity after a therapeutic trial of at least two standard cDMARDs in combination at optimal doses for 6 months (I). One of the failed cDMARDs must be methotrexate unless methotrexate is contraindicated (I).	I	A
Section 5 – Role of bDMARDs		
26. A bDMARD can be prescribed in patients who have inadequate response or intolerance to cDMARDs.	I	A
27. Early bDMARD use can be considered in patients who have active disease with poor prognostic factors.	IV	D
28. Prior to starting treatment with bDMARDs, history regarding active or current infections, comorbidities including tumors and malignancies, vaccinations, pregnancy, and possible contraindications should be obtained in all patients.	I	A
29. All patients should be screened for TB, and HBV and HCV infections before initiating bDMARD therapy.	I	A
30. Live vaccines should be given at least 4 weeks prior to bDMARD administration.	III–IV	C–D
31. Monotherapy or combination with methotrexate/cDMARDs: bDMARDs are most effective when combined with methotrexate.	I	A
32. In patients with RA who are candidates for bDMARD therapy, the therapeutic options include TNF antagonists, abatacept, rituximab and tocilizumab.	I	A
33. Patients who fail to achieve remission or low disease activity after 6 months of bDMARD therapy are recommended to switch to another bDMARD agent.	III	C
34. Dose reduction In patients who have achieved remission, a reduction in treatment should be considered.	I	A
If the patient remains in extended remission (> 12 months), tapering of bDMARDs can be considered.	II	B
35. Infectious complications: TB Screening for TB is recommended prior to starting bDMARD therapy.	II	B
All patients with latent TB infection should receive prophylactic anti-TB therapy.	II	B
Patients with active TB infection need to be adequately treated before consideration of bDMARD treatment.	III	C
36. Infectious complications: hepatitis Patients should be screened for HBV and HCV infections prior to the commencement of bDMARDs.	IV	D
bDMARDs should be avoided in patients with active or untreated chronic HBV infection and active HCV infection.	III	C
37. Active infections Active infections are contraindications for bDMARDs.	I	A
When an infection is suspected, based on clinical judgement, the bDMARD agent should be stopped and the patient must be treated appropriately.	IV	D
38. Pregnancy and lactation while on bDMARDs should only be considered after thorough assessment of benefits and risks.	IV	D
39. Vaccination Administration of all vaccines, if indicated, should, ideally, be undertaken at least 4 weeks before starting a bDMARD.	III–IV	C–D
Concurrent administration of live, attenuated vaccines is an absolute contraindication for patients being treated with bDMARDs.	IV	D
Section 6 – Role of tofacitinib		
40. Tofacitinib may be considered if a bDMARD has failed	II	B

ACPA, anti-citrullinated peptide antibodies; AP, Asia-Pacific; bDMARD, biological DMARD; COX-2 inhibitors, cyclooxygenase-2 inhibitors; cDMARD, conventional DMARD; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HBV, hepatitis B virus; HCV, hepatitis C virus; IM, intramuscular; NSAID, non-steroidal anti-inflammatory drug; RA, rheumatoid arthritis; RF, rheumatoid factor; TB, tuberculosis; TNF, tumor necrosis factor.

Summary of evidence linked to recommendation statement
Successful management of patients with RA depends upon empowering the patients with the knowledge about the chronic and fluctuating course of the disease,

treatment goal³¹ and, particularly, about the possible evolution and prognosis,²⁴ including side effects, costs of the drugs and the continuous need of physiotherapy.²² Offering verbal and written information to




Figure 2 (a) Algorithm summarizing the recommendations for treatment of patients with RA in the AP region. *Poor prognostic markers include positivity for ACPA or RF, increased ESR or CRP, radiological evidence of erosion or progression of erosions. ACPA, anti-cyclic citrullinated peptide antibody; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HCV, hepatitis C virus; LDA, low disease activity; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; TB, tuberculosis. (b) Algorithm summarizing the recommendations for treatment of patients with RA in the AP region (continued). DMARD, disease-modifying antirheumatic drug; LDA, low disease activity; MTX, methotrexate.

people with RA will improve their understanding of the condition and its management, and counter any misconceptions they may have.³²

Early treatment could improve the outcome of RA.^{23,29} Treatment with traditional DMARDs with or without low dose glucocorticoids should be considered as soon as the diagnosis of RA is made^{17,24,25,32} to increase clinical response and decrease radiographic progression.

Special comment/recommendation for the AP region

Early treatment of RA in this region may not be possible in some countries with poor economic status due to an inefficient referral system and a shortage of rheumatologists. The Steering Committee would, therefore, like to reinforce that this recommendation is aimed not only for rheumatologists but any clinicians who participate in the care of patients with RA. For many countries in the AP region, improving the knowledge of general clinicians of RA and its treatment is of utmost importance.

Recommendation 3. The choice of treatment is based on the findings of active disease and/or poor prognosis and comorbidities. (Level II; Strength B)

Supporting evidence

References 17, 18, 21–24 and 27–29.

Summary of evidence linked to recommendation statement

The presence of poor prognostic features should be assessed at baseline and considered when making treatment decisions. These include high disease activity state, (high number of swollen and tender joints, elevated erythrocyte sedimentation rate [ESR] or C-reactive protein [CRP]), rheumatoid factor (RF) positivity, anti-cyclic citrullinated peptide antibody (ACPA) positivity, and early presence of joint damage,^{17,18,21–24,28,29} extra-articular features (e.g., presence of rheumatoid nodules, vasculitis, Felty's syndrome) and functional limitation as measured by the Health Assessment Questionnaire Disability Index (HAQ-DI).^{18,23,28}

Special comment/recommendation for the AP region

Most RA patients in the AP region present late with it and many would have developed erosive disease. Basing radiological erosions solely as an indication for aggressive treatment may lead to over-treatment for some patients. Therefore, other markers of high disease activity and poor prognosis may be more appropriate indications for intensive DMARD treatment.

Recommendation 4. Poor prognostic factors include positivity for ACPA or RF, increased ESR or CRP, radiological evidence of erosion or progression of erosions. (Level II; Strength B)

Supporting evidence

References 17, 18, 21–24, 28, 29 and 34.

Summary of evidence linked to recommendation statement

Refer to Recommendation 3 above.

Special comment/recommendation for the AP region

In addition to comments made under Recommendation 3 above, clinicians should be aware of the widespread misuse of corticosteroid agents, many of which may be purchased over the counter or from a quack in the AP region, which may mask some of these poor prognostic factors.

Recommendation 5. All patients with recently diagnosed RA or active disease should be monitored for disease activity every 1 to 3 months. (Level I; Strength A)

Supporting evidence

References 18–20, 22, 24, 28, 32–37.

Summary of evidence linked to recommendation statement

At the beginning of RA treatment, especially in patients with high/moderate disease activity, the patient should preferably be assessed every month.^{19,20,24} The frequency of monitoring in patients with active RA should be 1 to 3 months,^{22,28,32–37} aiming to achieve remission by 6 months³³ when the interval for monitoring may be between 3 to 6 months, depending on the degree of disease activity.¹⁸

Special comment/recommendation for the AP region

Lack of resources in many countries in the AP region is a major obstacle for frequent monitoring of RA disease activity and treatment. Rheumatologists may need the assistance of general clinicians and allied health workers in the monitoring process, as well as a patient self-reporting system. The development of a good allied health worker and patient education program is of utmost importance in the overall management of patients with RA in this region.

Recommendation 6. A suitable and practical standardized measure of disease activity should be routinely

performed to assess patients response to treatment. (Level I; Strength A)

Supporting evidence

References 17–19, 21–24, 26–28, 32, 34–36 and 38–42.

Summary of evidence linked to recommendation statement

Most guidelines recommend the use of a validated composite score such as DAS28, SDAI and CDAI for measuring disease activity before starting treatment, and for monitoring disease activity and drug response after starting treatment.^{17,18,21–24,26–28,32,35,36,38–42} In addition, some guidelines recommend using the Health Assessment Questionnaire (HAQ) for evaluating the functional impact of the disease.^{21,32,36,41} The French guidelines also recommend anteroposterior X-rays of the hands, wrist and forefeet to monitor the course of RA; this may be done every 6 months until the end of the first year, then once every year until end of the third year, and thereafter every 2 to 4 years.⁴²

Special comment/recommendation for the AP region

Regular measurement of serum CRP may not be affordable in many AP countries. Rheumatologists from these countries are recommended to use ESR instead; otherwise, clinical activity measurement without ESR, for example, CDAI, should be used in patient monitoring.

Recommendation 7. All patients should be assessed clinically at presentation for extra-articular disease manifestations, comorbidities and infections, such as TB and hepatitis (Level II; Strength B). Information on vaccination status and special situations such as pregnancy and lactation should be obtained (Level II; Strength B)

Supporting evidence

References 18, 22–24, 29, 31, 33–35, 37, 38 and 43–59.

Summary of evidence linked to recommendation statement

Given that RA is a systemic disease accompanied with not only joint dysfunction but also other comorbidities (such as cardiovascular disease and osteoporosis), extra-articular manifestations (such as pericarditis, pleuritis and vasculitis), and an increased risk of infections,³² it is recommended to evaluate and screen patients for these conditions before initiating treatment with DMARDs, NSAIDs or corticosteroids.^{18,22–24,29,31,33–35,37,38,43–59}

As most drugs used in the treatment of RA are contraindicated during pregnancy and breastfeeding, it is recommended to rule out these situations before initiating

treatment.^{24,31,33–35,37,38,48,52–54,58} Before starting cDMARDs or bDMARDs, patients' vaccination status should be assessed and updated, and all killed, recombinant and live attenuated vaccinations undertaken.^{18,24,31,33,37,38,46,53,54,56}

Special comment/recommendation for the AP region

No region-specific comments.

Recommendation 8. Safety monitoring while patients are on bDMARD therapy is likewise recommended. (Level II; Strength B)

Supporting evidence

References 18, 22, 23, 32, 34, 35, 37, 43–47 and 60.

Summary of evidence linked to recommendation statement

Treatment with bDMARDs, particularly TNF inhibitors, is associated with an increased risk of certain infections, including TB, as well as that of non-Hodgkin's lymphoma and congestive heart failure.^{43,44} Thus, many guidelines recommend screening for active and latent TB before starting bDMARDs,^{18,22,23,34–37,43–47} and performing baseline hepatitis serology as well as other investigations, including a complete blood picture, liver function tests, serum urea and creatinine levels and antinuclear antibody status, and to rule out presence of active and latent infections and other comorbidities. Furthermore, continuous monitoring for these conditions and side effects is also emphasized during bDMARD therapy.^{18,22,23,32,34,35,37,43–47,60}

Special comment/recommendation for the AP region

It is especially important to monitor for the emergence of infective complications. Clinicians should be on the alert for not only TB and hepatitis infections but all other opportunistic infections, including fungal and parasitic infections.

Recommendation 9. Once the patient has improved symptomatically, treatment with corticosteroids and NSAIDs may be tapered, with the aim of eventually stopping these treatments. (Level II; Strength B)

Supporting evidence

References 17, 21, 22, 24–26, 28, 29, 32, 55, 57, 61 and 62.

Summary of evidence linked to recommendation statement

While NSAIDs in combination with DMARDs are effective in controlling pain and inflammation in RA,

long-term use is not recommended as these drugs are associated with significant gastrointestinal, cardiovascular and renal adverse effects.^{21,22,24,55,57,61} Furthermore, these agents have not demonstrated any efficacy in modifying the disease course.⁵⁷ Corticosteroids, in combination with DMARDs, are effective in limiting disease progression, and are particularly effective in decreasing inflammation in patients with flares and improving symptom control in those with early disease.⁵⁹ However, given the toxicity with long-term use, it is recommended to taper therapy as symptoms improve and discontinue completely once patients achieve remission.^{17,21,22,24–26,28,29,32,55,57,61,62}

Special comment/recommendation for the AP region

Clinicians should be aware of over-the-counter and quack-provided corticosteroid preparations, and their use must be discouraged.

Recommendation 10. If a patient is in sustained remission for more than 6 to 12 months after discontinuation of NSAIDs, corticosteroids and bDMARDs, then a gradual reduction in cDMARDs can be attempted with caution, as a shared decision between the patient and physician. (Level IV; Strength D)

Supporting evidence

References 17, 21, 22, 25, 26, 28, 32 and 55.

Summary of evidence linked to recommendation statement

Duration of remission is required for more than 1 year in the Indian 2008 guidelines,²² 6–12 months in the 2013 Brazilian guidelines²⁶ and over 6 months in the German 2013 guidelines.²⁵ The suggested sequence of drug withdrawal is NSAID, corticosteroid, bDMARD and then cDMARD.^{26,28} The reduction in treatment should be performed cautiously, gradually and in a stepwise manner. A shared decision must be reached between the patient and physician in this regard.^{17,25,28} According to the BeST study, sustained remission was defined as DAS < 1.6 for more than 6 months. According to the Indian guidelines, a minimum maintenance dose will be required for an indefinite period.²² The British Society for Rheumatology and British Health Professionals in Rheumatology (BSR-BHPR) guidelines warn about the frequent association of withdrawal with flare and disease progression.⁵⁵ The 2013 Brazilian guidelines describe withdrawal of cDMARD in exceptional situations.²⁶

Special comment/recommendation for the AP region

Because of the poor affordability of bDMARDs for most patients in this region, patients may rely more on cDMARDs for disease control. Thus, we recommend primarily cautious dose reduction but not complete cessation of cDMARDs for the majority of patients.

Section 2 – Role of NSAIDs (including cyclo-oxygenase-2 inhibitors)

Recommendation 11. NSAIDs and COX-2 inhibitors should be used at the lowest effective dose for the shortest possible period of time. (Level IV; Strength D)

Supporting evidence

References 29, 32 and 55.

Summary of evidence linked to recommendation

The National Institute for Health and Care Excellence (NICE) 2009 guidelines reviewed data from several studies to show that NSAIDs and COX-2 inhibitors were effective in treating the symptoms of RA and recommended that oral NSAIDs/COX-2 inhibitors be used in the lowest effective dose over the shortest period of time; it is advisable to use NSAIDs as needed.³² However, no optimum dose was proposed. The BSR 2006 and 2009 guidelines emphasized that long-term use of NSAIDs should be at the lowest effective dose and are best avoided because of the associated risks.^{29,55}

NSAIDs and COX-2 inhibitors, undoubtedly, are efficacious in controlling RA symptoms, but their gastrointestinal, cardiovascular and renal adverse effects are a matter of serious concern. A balanced approach should be undertaken whereby the benefits are weighed against the possible adverse effects.

Special comment/recommendation for the AP region

In the AP region, there is a general lack of awareness among patients and clinicians of the adverse effects associated with long-term NSAID use. Since NSAID use can mask symptoms by reducing inflammation,^{32,61} it can obscure RA progression and often delays referral from general practitioners. Availability of NSAIDs over the counter in many Asian countries also poses a significant challenge. Clearly, therefore, educating the public and allied healthcare workers is an important priority concern in this region.

Section 3 – Role of corticosteroids

Recommendation 12. Oral corticosteroid monotherapy is not recommended. (Level IV; Strength D)

Supporting evidence

References 17, 21, 22, 25, 28, 32, 57, 62 and 63.

Summary of evidence linked to recommendation statement

Advice from a rheumatologist must be obtained before treatment initiation with oral corticosteroids.⁶² The Latin American guidelines do not recommend corticosteroids as a sole disease-modifying agent.⁵⁷ The EULAR 2013 guidelines state that monotherapy is not specifically recommended and should only be used in exceptional cases when all other DMARDs are contraindicated.¹⁷ Other guidelines advise corticosteroid usage in combination with DMARDs.^{25,62}

Special comment/recommendation for the AP region

The use of corticosteroids in Asia poses particular risks. There is a widespread practice of self-medication as a result of ineffective control of the sales of prescription medications, leading to inappropriate use of corticosteroid agents.⁵⁷ Misuse of corticosteroids among clinicians in some AP countries is also widespread. It is, therefore, recommended that patients with suspected RA be assessed by a practitioner experienced in dealing with RA and not be put on corticosteroid monotherapy without a firm indication.

Recommendation 13. Oral corticosteroids can be considered to control active RA in combination with cDMARDs. (Level I; Strength A)

Supporting evidence

References 17, 21, 22, 25, 28, 32, 57, 62 and 63.

Summary of evidence linked to recommendation

Low-dose corticosteroids can be considered as part of the initial treatment strategy (in combination with one or more cDMARDs) for up to 6 months, but should be tapered as rapidly as clinically feasible.¹⁷ Short-term treatment with corticosteroids should be offered for managing flares in patients with recent-onset or established disease, to rapidly decrease inflammation.^{28,32}

For polyarticular flares, or at first presentation of the disease, intramuscular/intra-articular, or short oral courses of corticosteroids can decrease symptoms while waiting for other slower-acting drugs to take effect; this

is described as “bridging therapy”.^{17,22,23,25,32,57,62,63} Intra-articular injections are extremely useful for treating a flare in one or only a few joints.^{22,28,32} Injection into the same joint should not be repeated before 3 months, and it is advised that no more than three injections be administered per joint per year.²²

For severe extra-articular manifestations, intravenous corticosteroids can save critical organs (e.g., eyes in scleritis) or, occasionally, even life-threatening complications (e.g., severe serositis or vasculitis); however, corticosteroids should be used in combination with immunosuppressive agents such as cyclophosphamide.³²

In people with established RA, only continue long-term treatment with corticosteroids when: (a) the long-term complications of corticosteroid therapy have been fully discussed; and (b) all other treatment options (including bDMARDs) have been offered.³²

Special comment/recommendation for the AP region

No region-specific comments.

Recommendation 14. In early RA, the addition of low-dose corticosteroids (prednisolone \leq 7.5 mg/day) to cDMARDs leads to a reduction in radiographic progression. (Level I; Strength A)

Supporting evidence

References 17, 21, 22, 25, 28, 32, 57, 62 and 63.

Summary of evidence linked to recommendation

The EULAR 2010, Latin American and NICE guidelines discuss the evidence that low-dose prednisolone (< 7.5 mg daily) in patients with early RA does reduce radiographic progression over 2 years.^{32,57,63} According to the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) 2007 guidelines, corticosteroids are “probably effective in slowing radiographic progression in early and established RA”.²¹

Special comment/recommendation for the AP region

No region-specific comments.

Recommendation 15. Corticosteroids should be used in the lowest possible dose and tapered as rapidly as clinically feasible. (Level IV; Strength D)

Supporting evidence

References 17, 21, 22, 25, 28, 32, 57, 62 and 63.

Summary of evidence linked to recommendation statement

It is recommended to keep the requirement for continuing corticosteroid treatment under constant review, and titrate the dose against therapeutic response, risk of under-treatment and development of adverse events.¹⁷ However, the panel could not recommend an optimal tapering strategy based on the existing evidence. The Canadian 2012 and German 2013 guidelines recommend that corticosteroids should be used at the lowest possible dose and tapered as rapidly as possible.^{25,28} In contrast, the EULAR 2010 guidelines recommend slow tapering to avoid clinical relapses.⁶³

Special comment/recommendation for the Asia-Pacific region

This recommendation is particularly relevant in the AP region due to the widespread misuse of corticosteroids in some countries as stated above.

Section 4 – Role of cDMARDs

Recommendation 16. Treatment with cDMARDs as monotherapy or in combination should be started as soon as the diagnosis of RA is made. (Level I; Strength A)

Supporting evidence

References 17, 18, 21–26, 28, 29 and 57.

Summary of evidence linked to recommendation statement

Most of the guidelines recommend starting cDMARDs as soon as possible once the diagnosis of RA is confirmed.^{17,23,25,28,29,57} treatment should not be delayed by more than 3 months.²³ The ACR–EULAR 2010 classification criteria should be used to confirm diagnosis of RA and facilitate early introduction of effective therapy in RA. In patients with undifferentiated arthritis, the use of cDMARDs can be considered,²⁶ but in patients at risk of developing persistent and/or erosive arthritis, treatment with cDMARDs should be started as early as possible even if they do not fulfil the diagnostic criteria.²¹ In patients with early RA, cDMARD monotherapy is recommended in low and moderate disease activity, or high disease activity without poor prognostic markers.

Special comment/recommendation for the AP region

Delay in initiating cDMARD treatment for patients with RA in the AP region remains a major concern, primarily due to delay in the diagnosis of the underlying condi-

tion. Much work is needed to enhance public and clinician awareness of RA and its treatment.

Recommendation 17. Methotrexate is the first-line cDMARD for RA patients, and is considered as the anchor drug. (Level I; Strength A)

Supporting evidence

References 17, 21–29 and 57.

Summary of evidence linked to recommendation statement

Methotrexate is the preferred cDMARD with respect to efficacy and safety and should be the first cDMARD used in RA unless contraindicated;^{17,24–26,28} it is described as the “anchor drug”^{21,22,27} or “drug of choice”.^{24,57} DMARD-naïve patients should be started on methotrexate monotherapy, and treatment should be given for a duration of no less than 3 months at the maximally tolerated dose.²³ Choice of the first agent is based on the risk : benefit ratio with hydroxychloroquine an option in disease perceived as mild, and methotrexate or sulfasalazine in diseases adjudged moderate-to-severe, or likely to progress.²⁹

Special comment/recommendation for the AP region

Methotrexate used to be a taboo and thought to be excessively hepatotoxic in many AP countries. However, the efficacy and safety of this agent is now well established and methotrexate should be used unless contraindicated or there is poor tolerance.

Recommendation 18. Patients who cannot tolerate methotrexate may receive other cDMARDs such as leflunomide, sulfasalazine and hydroxychloroquine as first-line treatment (Level I; Strength A). Bucilamine, iguratimod, cyclosporin, azathioprine, intramuscular gold or tacrolimus may also be considered in some AP countries. (Level I; Strength B)

Supporting evidence

References 17, 23–26, 57 and 64–68.

Summary of evidence linked to recommendation statement

Patients without poor prognostic factors (i.e., with no erosions, are RF-negative, with low CRP levels, or with low disease activity) or those who cannot tolerate methotrexate may receive other cDMARDs, such as leflunomide, sulfasalazine, hydroxychloroquine or injectable gold.²³ The antimalarials hydroxychloroquine and chloroquine are less effective and should be

reserved for mild disease forms and diseases with low erosive potential.²⁴

Special comment/recommendation for the AP region

In many Asian countries, chloroquine may be recommended and is preferred to hydroxychloroquine or other cDMARDs due to its low treatment cost and high availability. In some AP countries, cDMARDs such as bucillamine and iguratimod, which are not available in Western countries, are widely used. Though these drugs have not been thoroughly evaluated outside their countries of origin, they have undergone rigorous testing locally and may also be the cDMARDs of choice for RA in the respective countries. For example, the efficacy of bucillamine can be judged within 3 months in moderately active RA patients either before or after methotrexate treatment.⁶⁴ Iguratimod is non-inferior in active RA patients when compared to methotrexate⁶⁵ or salazosulfapyridine.⁶⁶ Tacrolimus improves RA symptoms in patients with RA inadequately controlled with at least one prior cDMARD⁶⁷ and is well tolerated.⁶⁸

Recommendation 19. Pre-treatment investigations: complete blood count, liver function and renal function tests, viral hepatitis serology and chest radiograph should be ordered prior to initiating methotrexate therapy (Level II; Strength B).

Supporting evidence

References 22, 23 and 57.

Summary of evidence linked to recommendation statement

Pre-treatment investigations prior to initiating methotrexate should include complete blood count (CBC), liver function test (LFT) and renal function test (RFT), hepatitis B and C serology and chest X-ray.^{22,23,57} Other guidelines also consider screening for risk factors for cardiovascular diseases and osteoporosis,²³ and human immunodeficiency virus (HIV) in high-risk patients.²⁸ The pre-treatment investigations for other cDMARDs are: eye examination (funduscopy and perimetry) for antimalarials; and CBC, RFT and LFT for leflunomide, sulfasalazine, cyclosporine, and azathioprine. Blood pressure and serum creatinine should also be measured prior to initiating leflunomide and cyclosporine.²²

Special comment/recommendation for the AP region

The high prevalence of hepatitis and TB in the AP region provides the rationale for recommending the

pre-treatment investigations described above before starting methotrexate treatment.

Recommendation 20. Combination cDMARD therapy should be considered in patients with active RA, particularly those with poor prognostic factors. (Level I; Strength B)

Supporting evidence

References 17, 18, 23–25 and 28.

Summary of evidence linked to recommendation statement

If, after 3 months of cDMARD monotherapy (in patients without poor prognostic features), a patient deteriorates from low to moderate/high disease activity, then methotrexate, hydroxychloroquine or leflunomide should be added.¹⁸ A combination of cDMARDs (including double or triple therapy) may be considered in patients with very serious disease and poor prognostic factors.^{17,18,23–25,28} Patients with suboptimal treatment response should receive step-up therapy with combination therapy of methotrexate plus another agent (leflunomide, sulfasalazine, hydroxychloroquine).²³ Initial combination therapy with cDMARDs may also be considered, particularly in patients with poor prognostic features, moderate-to-high disease activity, and patients with recent-onset disease.

Special comment/recommendation for the AP region

Long-term treatment compliance with mono- or combination cDMARD therapy is a challenge in many AP countries. This may be related to the cost of treatment, anxiety about drug side effects and the need for regular monitoring. Patients should be educated about the disease and the need for uninterrupted treatment. Clinicians should explore this possibility and patients should also be reassured of the safety of the prescribed drugs, and encouraged to have adequate trials of cDMARD monotherapy before escalation to combination cDMARD therapy.

Recommendation 21. Combination cDMARD therapy should include methotrexate as the anchor drug unless methotrexate is contraindicated. (Level II; Strength B)

Supporting evidence

References 17, 18, 21–26, 28, 32 and 57.

Summary of evidence linked to recommendation statement

Most guidelines recommend methotrexate as the anchor drug unless it is contraindicated.^{17,18,21–24,26,28,57} Although direct comparisons between different regimens are lacking, combination cDMARD therapies, including methotrexate, have been proven to be superior to cDMARD monotherapy. Other combinations without methotrexate are not sufficiently evaluated. On the basis of guideline review, the panel recommends methotrexate combination therapy in patients who have inadequate response to methotrexate monotherapy.

The most commonly used cDMARDs in combination with methotrexate are hydroxychloroquine, sulfasalazine or their concurrent use. Leflunomide has also been studied in association with methotrexate. However, methotrexate combined with leflunomide should be cautiously used because of higher toxicity.^{69,70} Methotrexate-based combination therapies with azathioprine, cyclosporine A and intramuscular gold have been evaluated in at least one randomized controlled trial. The details of the regimens are listed in the ACR 2008, NICE 2009 and EULAR guidelines and a meta-analysis by Katchamart *et al.*^{32,69,71–73}

Special comment/recommendation for the AP region

As described above, cDMARDs available for treatment of RA extend to bucillamine, iguratimod and tacrolimus in certain AP countries. However, the use of these drugs combined with methotrexate or as an anchor drug in combination regimens has not been extensively studied and requires further evaluation.

Recommendation 22. Triple therapy with cDMARDs is an effective option in patients who show inadequate response to methotrexate monotherapy. (Level II; Strength B)

Supporting evidence

References 17, 18, 21–26, 28, 32 and 57.

Summary of evidence linked to recommendation statement

All the reviewed guidelines recommend changing regimen in patients who fail methotrexate monotherapy.^{17,18,21–26,28,32,57} The options include switching among cDMARDs and switching from cDMARDs to bDMARD agents. Combination cDMARD therapy can be an effective alternative to bDMARD therapy. In methotrexate-inadequate responders, methotrexate combination with one or two kinds of other cDMARDs was proven to be superior to methotrexate monother-

apy.⁷³ More recent data showed that triple therapy with cDMARDs had similar efficacy with bDMARD therapy.^{74–76} Although most recommendations did not specify the mandatory application of triple cDMARDs after methotrexate failure, current evidence suggests that triple therapy with cDMARDs may be able to substitute for bDMARD therapy.

The TACIT trial, which was published since the current consensus was reached, showed combination methotrexate and leflunomide was an equally effective regimen as methotrexate plus a TNF inhibitor.⁷⁷ This combination may also be considered as an alternative for triple combination cDMARDs.

Special comment/recommendation for the AP region

Because of the high cost and limited availability of bDMARDs in many AP countries, the panel recommends triple cDMARD therapy as an effective option for patients with inadequate response to methotrexate.

Recommendation 23. Patients should be assessed every 1 to 3 months after the initial treatment or change of regimen until the disease is stabilized, in remission or in low disease activity state. (Level I; Strength A)

Supporting evidence

References 17–19, 21, 24–26, 28, 32 and 72.

Summary of evidence linked to recommendation statement

One systematic review of trials on strategy-driven treatment approaches in RA concluded that intensive steering (treatment target, follow up method) and intensive medication strategies in early active RA produces a better clinical outcome, improved physical function and less structural damage.⁷⁸

Early-stage active RA can be monitored monthly.^{19,24,26,31} Radiographs of joints are recommended as frequently as every 6 to 12 months during the first few years^{21,28} or annually¹⁹ to estimate potential progression of joint damage.

Special comment/recommendation for the AP region

The shortage of rheumatologists in many AP countries represents a major hurdle to the frequent monitoring of RA patients. As indicated earlier, an effective educational program for patients and other healthcare providers, including general practitioners and allied health workers, is urgently needed in many AP countries.

Recommendation 24. Patients who have been stabilized or are in remission or low disease activity can be monitored every 3 to 6 months. (Level IV; Strength D)

Supporting evidence

References 17, 19, 24, 26, 28, 32 and 55.

Summary of evidence linked to recommendation statement

Most guidelines agree that monitoring can be less frequent once the treatment target has been stabilized. However, the suggested monitoring intervals are variable and may only represent the compromise of expert opinion (IV, D). According to the Canadian guidelines, patients in remission can be monitored at longer intervals without further specification.²⁸ The Brazilian guidelines suggest monitoring every 3 months for controlled disease.^{25,26} The treat-to-target guidelines consider less frequent monitoring such as every 3 to 6 months for patients in sustained, low disease activity or remission.¹⁹ The EULAR 2013 guidelines propose monitoring every 6 to 12 months once the treatment target has been stabilized.¹⁷ The BSR-BHPR 2009 and NICE guidelines recommend annual review.^{32,55}

Special comment/recommendation for the AP region

No region-specific comments.

Recommendation 25. Definition of treatment failure: inadequate response with cDMARDs is defined as failure to achieve remission or low disease activity after a therapeutic trial of at least two standard cDMARDs in combination at optimal doses for 6 months (Level I; Strength A). One of the failed cDMARDs must be methotrexate unless methotrexate is contraindicated. (Level I; Strength A)

Supporting evidence

References 17, 18, 21–26, 28, 32, 34, 35, 52 and 57.

Summary of evidence linked to recommendation statement

Six guidelines define treatment target as remission or low disease activity; thus, any other status would be inadequate response/treatment failure.^{18,24–26,28,57} Three guidelines define target as remission.^{17,21,23} The required treatment usually includes at least methotrexate monotherapy unless not tolerated;^{18,28,34,35} or in combination with another cDMARD.^{17,18,22–24,26,28,32,48,52} The treatment duration, at a standard target dose, may be at least 3 months^{18,23,28,34,35,48,57} or 6 months.^{17,22,23,26,31,52}

Special comment/recommendation for the AP region

No region-specific comments.

Section 5 – Role of bDMARDs

Recommendation 26. A bDMARD can be prescribed in patients who have inadequate response or intolerance to cDMARDs. (Level I; Strength A)

Supporting evidence

References 17, 18, 22, 23, 25, 26, 28, 31, 33–36, 38, 39, 48–51, 53, 54, 56–58 and 79.

Summary of evidence linked to recommendation statement

The BSR 2010 guidelines recommend starting a TNF inhibitor in those who have active RA and have inadequate response to cDMARDs.³⁹ Inadequate response is defined as DAS28 > 3.2 with ≥ 3 tender and swollen joint counts, and being treated with at least two cDMARDs (one should be methotrexate unless contraindicated) in combination over a 6-month period, and at a standard dose for at least 2 months, unless a significant toxicity occurs and limits the dose and duration of treatment. Rituximab (anti-CD20) should be prescribed in a patient who has inadequate response or intolerance to at least one TNF inhibitor,⁵⁸ and still has active disease defined by DAS28 ≥ 3.2 or SDAI > 11 or similar indices. Tocilizumab (anti-IL-6) is recommended for those who have moderate or severe disease activity, according to a validated composite measure, and have had inadequate response or intolerance to at least one cDMARD or TNF inhibitor. Abatacept (CTLA-4Ig) is recommended for those who have moderate or severe disease activity, according to a validated composite measure, and have had inadequate response or intolerance to at least one cDMARD or TNF inhibitor.

Special comment/recommendation for the AP region

As has been stated above, as a result of the high cost and limited availability of bDMARDs in many AP countries, triple cDMARD combination therapy may be considered for patients in whom bDMARDs are indicated.

Recommendation 27. Early bDMARD use can be considered in patients who have active disease with poor prognostic factors. (Level IV; Strength D)

Supporting evidence

Reference 18.

Summary of evidence linked to recommendation statement

In 2012, the ACR suggested that TNF inhibitors, with or without methotrexate, may be considered in patients with early RA (duration < 6 months) and high disease activity and poor prognostic features. This recommendation is based on expert opinion as the data on the use of TNF inhibitors in early RA patients with active disease and poor prognostic factors are limited.¹⁸

Special comment/recommendation for the AP region

Once again, for countries with poor socioeconomic status and where the reimbursement system is inadequate, combination cDMARD therapies, including triple therapy, may be considered for these patients instead.

Recommendation 28. Prior to starting treatment with bDMARDs, history regarding active or current infections, comorbidities including tumors and malignancies, vaccinations, pregnancy, and possible contraindications should be obtained in all patients. (Level I; Strength A)

Supporting evidence

References 18, 21, 22, 24, 26, 31, 33, 35, 38, 46, 48–50, 53, 54, 56 and 57.

Summary of evidence linked to recommendation statement

Reports on the risk of serious infections and the development of malignancies in RA patients receiving bDMARD therapy, particularly TNF inhibitors, showed conflicting results. A meta-analysis showed the use of TNF inhibitors is associated with increased risk of serious infections,^{80,81} but another meta-analysis could not confirm this finding.⁸²

A meta-analysis of randomized controlled trials found that the point estimate of malignancy risk was higher in etanercept-treated patients than in controls,⁸³ but two recent meta-analyses failed to confirm these findings.^{84,85}

Regarding pregnancy, data from the BSR Biologics Register found that the incidence of spontaneous loss among those who were prior exposed to TNF inhibitors was higher than in controls (17% *vs.* 10%), but without risk of significant congenital abnormalities. Nevertheless, they recommended that pregnancy be avoided during anti-TNF therapy.⁸⁶

A study on the effect of high-dose TNF inhibitor (infliximab) showed a detrimental effect on congestive heart failure,⁸⁷ however, two recent studies could not confirm this finding.^{88,89}

Rituximab may be used in RA patients with lymphoma⁴⁶ and should be avoided in those with hypogammaglobulinemia or low CD4 counts.⁵⁶ Tocilizumab should be avoided in those with a history of bowel perforation.^{24,33,48}

Special comment/recommendation for the AP region

It is of particular importance that clinicians have a high level of alertness of pre-existing infectious diseases, including uncommon infections, and other comorbidities in AP patients receiving bDMARDs because of differences in the pattern and frequency of occurrence of these conditions in this region.

Recommendation 29. All patients should be screened for TB, and hepatitis B and C virus infections before initiating bDMARD therapy. (Level I; Strength A)

Supporting evidence

References 18, 22–24, 28, 31, 33, 34, 38, 43, 46, 48–50, 52–54 and 56–58.

Summary of evidence linked to recommendation statement

Overall, 22 studies recommended screening for infections that included TB, HBV and HCV infections prior to starting bDMARD therapy.^{18,22–24,28,31,33,34,38,43,46,48–50,52–54,56–58} In Japan, testing for beta D-glucan is also recommended prior to initiating TNF inhibitors and tocilizumab (anti-IL-6).^{48,49}

Special comment/recommendation for the AP region

The AP region is endemic for TB. Therefore, active and latent TB should be evaluated and treated properly, according to each individual country guideline, prior to commencement of bDMARDs.

Recommendation 30. Live vaccines should be given at least 4 weeks prior to administration of bDMARD agents. (Level III–IV; Strength C–D)

Supporting Evidence

References 18, 22–24, 31, 33–35, 37, 38, 43, 46, 48, 52, 55, 56 and 58.

Summary of evidence linked to recommendation statement

Patients who are immunocompromised are at risk of disseminated infection with live attenuated vaccines. All guidelines reviewed emphasized that concurrent administration of live attenuated vaccines was not recommended in patients receiving bDMARDs. Most guidelines agree that live attenuated vaccines should be, ideally, given 4 weeks prior to initiation of bDMARDs

but the level of evidence for this remained low (Level IV).

Patients already on bDMARDs who require live vaccines should only receive it 6 months after the last infusion of infliximab or 23 weeks after the last dose of etanercept.^{22,46,52} There was no guidance on how long to discontinue other bDMARD agents, although the Canadian guidelines recommend that the timing for withholding/restarting therapy should be based on the pharmacokinetic properties of the agent used.

In the rare event when a live vaccine may be required urgently in a patient on bDMARDs (e.g., outbreak or urgent travel), discussion about the risks and benefits should be undertaken with the patient in consultation with an infectious disease physician.

Special comment/recommendation for the AP region
No region-specific comments.

Recommendation 31. Monotherapy or combination with methotrexate/cDMARDs: bDMARDs are most effective when combined with methotrexate. (Level I; Strength A)

Supporting evidence

References 17–19, 21, 23–26, 28, 29, 31–33, 35, 36, 38, 48, 51, 52, 56 and 57.

Summary of evidence linked to recommendation statement

The guidelines reviewed recommend the use of methotrexate in combination with bDMARD agents. This combination is associated with significant benefits in terms of control of disease activity, improved function and quality of life as well as retardation of radiographic progression.^{17,32} Methotrexate is also believed to reduce development of human anti-chimeric antibody (HACA) in patients receiving infliximab.⁵¹ In the CONCERTO trial that enrolled early RA patients receiving adalimumab plus methotrexate, an increasing trend of efficacy was observed with increased doses of methotrexate. However, the efficacy of the 10 mg weekly dose of methotrexate was equivalent to the 20 mg weekly dose.¹⁷

In cases where methotrexate is contraindicated, several guidelines mention that alternative cDMARDs such as leflunomide, sulfasalazine, azathioprine and cyclosporine can be combined with bDMARD agents.^{36,56} In addition, adalimumab, etanercept and certolizumab have been approved as monotherapy^{18,25,38,56} and toci-

lizumab has, likewise, been used as monotherapy for patients with RA.^{17,23,25,33,48}

Special comment/recommendation for the AP region
Please refer to recommendations 18 and 21.

Recommendation 32. In patients with RA who are candidates for bDMARD therapy, the therapeutic options include TNF inhibitors, abatacept, tocilizumab and rituximab. (Level I; Strength A)

Supporting evidence

References 17–19, 21, 23–26, 28, 29, 31–33, 35, 36, 38, 48, 51, 52, 56 and 57.

Summary of evidence linked to recommendation statement

In the ACR 2012 guidelines, TNF inhibitors may be used as initial treatment for patients with early RA (< 6 months' duration) who present with high disease activity and poor prognostic factors).¹⁸ TNF inhibitors provide the most robust efficacy and safety among all bDMARD agents for RA. However, recent data have shown other bDMARD agents such as abatacept and tocilizumab have sufficient and comparable efficacy and safety data and can be considered as first-line bDMARD agents.^{17,25} The use of rituximab as first-line bDMARD therapy has been described in certain circumstances, such as in patients with history of lymphoma, demyelinating disease or TB which precludes the use of other bDMARD agents.^{17,56}

Special comment/recommendation for the AP region

Patient preference and cost of treatment should always be considered when choosing a particular bDMARD. Several countries may have problems in sustaining the use of bDMARDs due to non-reimbursement.

Recommendation 33. Patients who fail to achieve remission or low disease activity after 6 months of bDMARD therapy are recommended to switch to another bDMARD agent. (Level III; Strength C)

Supporting evidence

References 17, 18, 23–25, 28, 29, 31, 33, 34, 36, 38, 44, 52–54, 57 and 58.

Summary of evidence linked to recommendation statement

In the era of treat-to-target in RA, a significant delay should not be allowed before switching therapy in patients who have not achieved an adequate response. Most guidelines suggest a timeline of 12 weeks. The

ACR guidelines separated the duration of failure with a TNF inhibitor (3 months) and a non-TNF inhibitor bDMARD (6 months) as it was felt that the response to treatment to non-TNF inhibitor bDMARDs may take longer.¹⁸

Observational studies have suggested that switching to a second TNF inhibitor after failure of the first may be a feasible option. There are no controlled trials to compare switching to a second TNF inhibitor or a bDMARD agent of another mode of action, so the choice should be based on a shared decision between the patient and the physician based on patient's preferences and characteristics. The EULAR recommendations emphasize that no preference is stated.¹⁷

Two guidelines specifically looked at switching to another bDMARD after failure of rituximab.^{31,58} Early studies suggested a numerical but not statistically significant increase in infections with the use of TNF inhibitors after rituximab but further follow up showed that there was no difference in incidence of infection. Data from registries suggest that use of abatacept after rituximab is also safe, but further data are needed.

Special comment/recommendation for the AP region

Biosimilars may be available in certain AP countries. They may be considered because of their comparatively lower cost. However, the use of these agents must also be based on available evidence. This will be discussed in a subsequent APLAR statement.

Recommendation 34. Dose reduction: in patients who have achieved remission, a reduction in treatment should be considered. (Level I; Strength A). If the patient remains in extended remission (> 12 months), tapering of bDMARDs can be considered. (Level II; Strength B)

Supporting evidence

References 21, 28, 29, 34–37, 44 and 52.

Summary of evidence linked to recommendation statement

Of the 10 guidelines which discussed tapering of treatment in the case of sustained remission, several recommend that corticosteroids and/or NSAIDs should be tapered first.^{28,29,34–37,44,52} Some, but not all, recommend tapering of bDMARDs in patients with sustained remission.^{21,29,35,37,44,52} The issue of withdrawal after remission is reached remains inadequately researched

and is stated as an item in the 'research agenda' in the EULAR 2013 guidelines.¹⁷

Special comment/recommendation for the AP region

As has been highlighted earlier, long-term bDMARDs are not often affordable by most patients in the AP region. They often request their clinician to taper or even stop their treatment early. While awaiting further data to become available, the Steering Committee recommends that tapering should only be considered if a patient has remained in disease remission for at least 12 months.

Recommendation 35. Infectious complications: TB

Screening for TB is recommended prior to starting bDMARD therapy. (Level II; Strength B) All patients with latent TB infection (LTBI) should receive prophylactic anti-TB therapy. (Level II; Strength B) Patients with active TB infection need to be adequately treated before consideration of bDMARD treatment. (Level III; Strength C)

Supporting evidence

References 18, 22–24, 28, 35, 37, 43, 45–47 and 48–52.

Summary of evidence linked to recommendation statement

The most common criteria for "LTBI" included a weal > 10 mm (different guidelines/consensus/recommendations suggested different cut-off values for tuberculin skin testing [TST]; the Hong Kong recommendations used 10 mm induration for immunocompetent patients and 5 mm for patients who are significantly immunocompromised such as those with HIV infection; the French 2003 TNFi and Latin American 2006 guidelines also suggested 10 mm; the Japanese 2007 guidelines suggested 20 mm; the French 2007, Portuguese 2011 and Brazilian 2012 guidelines used 5 mm; the Philippine 2006 guidelines suggested 8 mm) or a blister in response to a TST done more than 10 years after the last Bacille-Calmette Guérin (BCG) vaccination, with no history of correct treatment for active TB, or residual radiographic TB lesions > 1 cm in size with no certainty.⁴⁹

TNF inhibitors, particularly the monoclonal antibodies, have been found to be associated with increased incidence of TB.⁹⁰ Prophylaxis with anti-TB drugs with an accepted regimen, such as isoniazid 300 mg/day is recommended at least 1 month prior to starting TNF inhibitors and other bDMARD agents and be

maintained for 9 months in RA patients with occult TB infection.

Special comment/recommendation for the AP region

The AP region has a high prevalence of active TB infections. Thus, the proportion of patients at risk for TB infection and re-infection during bDMARD therapy is higher when compared with Europe and North America.

The high cost and limited availability of interferon-gamma release assay (IGRA) and the lack of timely access to infectious disease specialists may be barriers to the accurate diagnosis of latent TB infection. Nevertheless, a chest X-ray and TST are the minimum requirements for screening for LTBI.

The common practice of administration of the BCG vaccine across many AP countries may lead to a high false-positive rate for TST. Thus, many AP countries have set a higher cut-off value for LTBI screening purposes. Clinicians are therefore recommended to refer to their national guidelines for their respective criteria for LTBI based on TST results. Where such guidelines are unavailable, the committee recommends using the development of a wheal > 10 mm following TST as the cut-off value for LTBI warranting the use of prophylactic anti-TB antibiotics prior to bDMARD treatment.

The issue of TB infections and RA treatment will be dealt with in a subsequent APLAR recommendation report.

Recommendation 36. Infectious complications: Hepatitis

Patients should be screened for HBV and HCV infections prior to the commencement of bDMARDs. (Level IV; Strength D) bDMARDs should be avoided in patients with active or untreated chronic HBV infection and active HCV infection. (Level III; Strength C)

Supporting evidence

References 18, 22–24, 31, 33, 35, 37, 43, 48, 51, 52, 56 and 58 addressed the topic of hepatitis-related complications associated with bDMARD use, but no evidence was identified to support this statement.

Summary of evidence linked to recommendation

Although there was some evidence, most is in the form of case reports, some of which are contradictory.

Special comment/recommendation for the AP region

Patients with evidence of chronic viral hepatitis B infection, including serum positivity for hepatitis B surface

antigen or anti-hepatitis core antibodies, should be given appropriate anti-viral treatment while on bDMARD therapies. The cost of anti-viral treatment plus the need for regular monitoring, including blood hepatitis B DNA detection, will further lower the affordability of bDMARDs for many RA patients in this region. While appreciating the very high cost of anti-HCV treatments, they should be considered in HCV-infected patients prior to dDMARDs.

The timely access to infectious disease and hepatology specialists is not always possible in many AP countries. Rheumatologists need to stay vigilant of these infections when starting bDMARDs for these patients.

Recommendation 37. Active infections are contraindications for bDMARDs. (Level I; Strength A) When an infection is suspected, based on clinical judgement, the bDMARD agent should be stopped and the patient must be treated appropriately. (Level IV; Strength D)

Supporting evidence

References 25, 26, 35, 37, 38, 43, 48–52 and 57.

Summary of evidence linked to recommendation

Of the 48 RA management recommendation reports, 11 discussed non-TB, non-hepatitis infections.^{25,26,35,37,43,48–52,57} Active infections as contraindications for bDMARDs were discussed in four recommendations.^{35,38,48} Besides, past history of serious infections in the last 6 months and history of pneumocystis pneumonia (PCP) were identified as contraindications for bDMARDs in four guidelines.^{48–50}

Compared with the general population, patients with RA have an increased risk of infection, which is nearly twice as high as that observed in matched non-RA controls.^{91,92} When considering serious infections, a trend toward an increased frequency compared to cDMARDs has been noted regarding monoclonal anti-TNF antibodies,^{93–95} with a significant increase reported in two previous studies with infliximab and adalimumab.^{96,97} These findings are consistent with the results of a meta-analysis published in 2006 that included all randomized controlled trials performed with infliximab and adalimumab.⁸⁰

Special comment/recommendation for the AP region

While there is no prevalence data from the AP region of several transmissible diseases such as leprosy, malaria, Chagas' disease, schistosomiasis, yellow fever, dengue

fever, filariasis and helminthic infections, we recommend physicians to remain alert regarding these conditions so as to allow timely diagnosis and appropriate treatment.

Recommendation 38. Pregnancy and lactation while on bDMARDs should only be considered after thorough assessment of benefits and risks. (Level IV; Strength D)

Supporting evidence

References 22, 24, 31, 33, 37, 38, 43, 48, 51, 52, 57 and 58.

Summary of evidence linked to recommendation

There is an inherent inadequacy of safety data on bDMARD agents during pregnancy because pregnant women as a group are excluded from the majority of premarketing clinical trials and safety studies for ethical reasons. However, most recommendations stated that pregnancy and lactation should be avoided while on bDMARDs and effective contraception is strongly

recommended to prevent pregnancy in women with childbearing potential until more safety data are available.

Special comment/recommendation for the AP region

Earlier, the Steering Committee suggested the consideration of triple combination cDMARDs as an alternative to bDMARDs because of cost and availability concerns. It should be noted that cDMARDs are as potentially, or more, toxic than bDMARDs.⁹⁸

Recommendation 39. Vaccination: administration of all vaccines, if indicated, should, ideally, be undertaken at least 4 weeks before starting a bDMARD. (Level III–IV; Strength C–D) Concurrent administration of live, attenuated vaccines is an absolute contraindication for patients being treated with bDMARDs. (Level IV; Strength D)

Supporting evidence

References 18, 22–24, 31, 33–35, 37, 38, 43, 46, 48, 52, 55, 56, 58.

Table 4 Research agenda for some of the 40 treatment recommendations for RA patients in the AP region

I. General RA treatment strategies

Longitudinal studies of the socioeconomic cost of RA

Prevalence of use of complementary, over-the-counter and self-medications for RA

Setting a realistic treatment target for patients from countries with low resources

Evaluation of the role of non-rheumatologists and allied health workers in RA management

II. Role of NSAIDs

The use of NSAIDs and their short- and long-term side effects (much of this has already been carried out previously)

III. Role of corticosteroids

The prevalence of corticosteroid abuse

Evaluation of the effects of long-term low-dose corticosteroids

IV. Role of cDMARDs

Do Asian patients tolerate methotrexate less well?

Efficacy of combination cDMARDs involving agents such as bucillamine, iguratimod, intramuscular gold or tacrolimus

Effects of cDMARDs on TB reactivation and novel infections

Effects of cDMARDs on chronic viral hepatitis carriers

Comparison of the efficacy of triple cDMARD combination and biologic agents

V. Role of bDMARDs

Effects of bDMARDs on TB reactivation and novel infections

Effects of bDMARDs on chronic viral hepatitis carriers

The frequency and occurrence of infective complications, including opportunistic infections associated with bDMARD use

The frequency and occurrence of malignant conditions associated with bDMARD use

Dose titration of bDMARDs

VI. Role of tofacitinib

The efficacy and long- and short-term side-effect profile of tofacitinib

The efficacy of tofacitinib in bDMARD failure patients

The possible role of tofacitinib in bDMARD-naïve patients

bDMARD, biological DMARD; cDMARD, conventional DMARD; DMARD, disease-modifying antirheumatic drug; NSAID, non-steroidal anti-inflammatory drug; RA, rheumatoid arthritis; TB, tuberculosis.

Summary of evidence linked to recommendation

Overall, there is a lack of data on the safety of vaccination during treatment with most bDMARDs. Furthermore, there are not many studies on the efficacy of vaccines during treatment with bDMARDs; a study on pneumococcal vaccination suggested that patients on TNF inhibitors may not respond adequately to vaccination.⁹⁹ Thus, the recommendation of the Steering Committee in this regard aligns with that of most guidelines and is predominantly based on expert opinion.

Special comment/recommendation for the AP region

No region-specific comments.

Section 6 – Role of tofacitinib

Recommendation 40: Tofacitinib may be considered if a bDMARD has failed. (Level II; Strength B).

Supporting evidence

This recommendation is made not based on a review of the treatment recommendations/guidelines that the Steering Committee had initially identified. However, the role of tofacitinib was included in the EULAR RA treatment recommendations 2013 update.¹⁷

Summary of evidence linked to recommendation statement

Tofacitinib, a JAK inhibitor, has been under investigation as a therapy for RA. It is not a bDMARD or a cDMARD. In a number of placebo-controlled studies, tofacitinib, used either as a monotherapy or in combination with a cDMARD, primarily methotrexate, was associated with reductions in signs and symptoms of RA and improvement in physical function in patients with active disease despite previous treatment with cDMARDs.^{100–102} In another study of active disease-patients receiving background methotrexate, tofacitinib was found to be significantly superior to placebo and was numerically similar to adalimumab in efficacy.¹⁰³ Furthermore, in a 6-month, double-blind, parallel-group phase 3 study involving 266 patients who were TNF inhibitor refractory, tofacitinib use was associated with meaningful improvements in signs and symptoms of RA and physical function.¹⁰⁴ However, the efficacy of this agent in other bDMARD refractory RA patients has not been reported.

Special comment/recommendation for the AP region

While there is evidence that tofacitinib is useful in active RA disease patients who have failed cDMARDs, and probably those who are refractory to TNF inhibi-

tors, more data is needed to support its use as a first-line DMARD or after a patient has failed a bDMARD, specifically the non-TNF inhibitors. While we await long-term data on the efficacy and side-effect profiles, particularly infectious disease complications, of tofacitinib, the Steering Committee felt it is not yet ready to recommend its use in DMARD-naïve patients. The other consideration is to do with the possible high financial cost of tofacitinib which is significantly higher than that of all cDMARDs. This is an important consideration for many AP countries where there are financial constraints in obtaining access to expensive medications. Our decision to recommend its use in patients who have failed a bDMARD is based on an extrapolation of the data reported by Burmester *et al.*¹⁰⁴ The Steering Committee encourages national societies to include tofacitinib in their national drug formulary.

DISCUSSION

These are the first RA treatment recommendations developed by APLAR. The AP region is unique in many ways. It accounts for 61% of the world population with diverse ethnic, cultural and socioeconomic variations.¹⁰⁵ The prevalence, clinical manifestations, response to treatment and outcome of RA patients in many Asian countries have been suggested to differ from those reported in the West. Importantly, rheumatology is still a developing medical subspecialty in the region with a severe shortage of trained rheumatologists in many countries.¹⁰⁶ Not only are many RA patients in the AP region managed by non-rheumatologists, the lack of resources also means RA clinical studies are sparse and that a big gap exists in the evidence-based management of RA in this region.

The primary aim of these treatment recommendations is to provide clinicians with an evidence-based reference for the treatment of RA in the AP region. The Steering Committee was comprised of rheumatologists from 12 AP countries representing a diverse spectrum of cultures and ethnicities, health economic statuses and practises of rheumatology in the region. A patient with RA was also invited to join the Committee so as to include patients' perspectives on the treatment of their condition in the recommendations. Because of the nature of the recommendation drafting process which required members to communicate in English, a patient from Hong Kong who was literate in the language was invited to join the Committee.

The Steering Committee did not perform a systematic review of original articles to inform recommendations. Instead, the recommendations were developed using the ADAPTE framework^{12,13} appraising all international RA practice guidelines and recommendations through to December 2013. The ADAPTE Collaboration is an international collaboration of researchers, guideline developers and guideline implementers who aim to promote the development and use of clinical practice guidelines through the adaptation of existing guidelines. Having first established the scope and purpose of the current RA treatment recommendations, the Steering Committee conducted a thorough search for guidelines and relevant documentations that have been previously published. Each of these articles was then assessed for guideline quality, currency, content, consistency and acceptability/applicability for the AP region using the AGREE instrument.¹⁵ Selected previous guidelines were rigorously and systematically reviewed and discussed by members of the Steering Committee before they were customized to create the current adapted recommendations. The generic adaptation process of ADAPTE has been shown to be valid and of high quality.^{12,13}

Based on the key questions that the Steering Committee had identified regarding the treatment of RA in the AP region, 40 recommendations concerning the general RA treatment strategies, and the role of NSAIDs, corticosteroids, cDMARDs, bDMARDs and tofacitinib have been made. Specific issues relating to the safety and monitoring of cDMARDs and bDMARDs are not covered in the current report. These include screening and prophylactic treatment for latent TB, management of patients who are chronic viral hepatitis B/C carriers and precautions with other regional prevalent infectious diseases. These will be covered separately in a later instalment of the recommendations.

The role of tofacitinib, a JAK inhibitor, in RA was not originally included as one of the key questions. However, midway through the development of these recommendations, tofacitinib became available in a number of AP countries and a recommendation on the use of this agent was included in the EULAR RA treatment recommendations 2013 update. The Steering Committee therefore felt it would be appropriate to include the role of tofacitinib in RA treatment in the current recommendations.

Realizing that many Asian countries are under-resourced to allow them to adhere strictly to the recom-

mendations made in this report, the Steering Committee added comments based on expert opinions and consensus following each recommendation in the hope that minimum care requirement is achieved for all RA patients in these countries. In addition, it is hoped that some of these region-specific comments, which may lack full evidence, may form the basis of a research agenda, which is by no means exhaustive, for clinicians in the AP region (Table 4).

It should be noted that the current report does not include recommendations for physical and occupational treatment, and alternative/complementary therapies which are widely practised by many patients in the AP region. This is partly because evidence on the role of these treatment modalities is sparse. Furthermore, in many AP countries, the physical and occupational therapy disciplines are poorly developed. However, where physical and other non-pharmacological therapies are available, clinicians should advise RA patients about their roles in protecting normal joint function. For example, the BSR 2005 guidelines mentioned that patients should be informed about alternative techniques of effective pain management, including transcutaneous nerve stimulation (TENS) and behavioral approaches.⁶⁰ Others have also found that physical therapy and exercise are beneficial in RA patients.⁵⁷ Where resources are limited and patients are unable to afford the cost of procedures such as TENS, patients may be advised to exercise at home, as leisure time physical activity has also been shown to be beneficial and should be encouraged.²²

CONCLUSION

APLAR has developed a set of general recommendations for the best practise management of RA in the AP region. We are also hopeful that some of these recommendations, where evidence for this region may be lacking, may stimulate clinicians to embark on research studies to resolve them. Specific issues such as the prevention of reactivation or novel TB and viral hepatitis infections will be addressed in a second instalment.

ACKNOWLEDGEMENTS

We would like to thank the Asia Pacific League of Associations for Rheumatology (APLAR) for funding this project, Ms King Chu Chan for serving as a patient representative on the Steering Committee, Dr Josef Smolen

and Dr Vibeke Strand for reviewing the recommendations, and Dr Pradnya Kulkarni and Mr Chris Facey of MIMS (Hong Kong) Limited for providing medical writing support.

FUNDING

APLAR and unrestricted educational grants from the following pharmaceutical companies: AbbVie, Janssen, Pfizer, Roche and UCB.

CONFLICT OF INTEREST

All authors have disclosed any conflicts of interest. The individual declarations are summarized below. CSL has received unrestricted educational grants from AbbVie, Janssen-Cilag, Pfizer, Roche and UCB, and personal fees from Abbvie, Bristol-Myers Squibb, Celltrion, GlaxoSmithKline, Pfizer, Roche, Sanofi-Aventis and UCB; AH has received grants from Roche, and personal fees from Abbvie and Pfizer; MK has received personal fees from AbbVie, Astellas, Bristol-Myers Squibb, Chugai, Eisai, Janssen, Ono, Pfizer, Santen and Tanabe-Mitsubishi; JJJ has received personal fees from Janssen, Pfizer and Roche; WL has received personal fees from Janssen, Pfizer, Roche and Sanofi-Aventis, and investigator fees from Janssen, Pfizer and Roche; PN has received research grants and personal fees from Pfizer; PS has received research grants from Pfizer. All other authors declare no conflict.

CONTRIBUTIONS

All authors were involved in performing the literature search, appraisal of guideline quality, grading of evidence, evidence synthesis, development of recommendations, and writing and proofreading of recommendations.

REFERENCES

- McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. *N Engl J Med* 365, 2205–19.
- Turesson C, Jacobsson L, Bergström U (1999) Extra-articular rheumatoid arthritis: prevalence and mortality. *Rheumatology (Oxford)* 38, 668–74.
- Moreland L (2005) Unmet needs in rheumatoid arthritis. *Arthritis Res Ther* 7 (Suppl. 3), S2–8.
- Salaffi F, Carotti M, Gasparini S *et al.* (2009) The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. *Health Qual Life Outcomes* 7, 25.
- Filipovic I, Walker D, Forster F *et al.* (2011) Quantifying the economic burden of productivity loss in rheumatoid arthritis. *Rheumatology (Oxford)* 50, 1083–90.
- Gettings L (2010) Psychological well-being in rheumatoid arthritis: a review of the literature. *Musculoskeletal Care* 8, 99–106.
- Smolen JS, Aletaha D, Koeller M *et al.* (2007) New therapies for treatment of rheumatoid arthritis. *Lancet* 370 (9602), 1861–74.
- Flavell KJ, Biddulph JP, Powell JE *et al.* (2001) South Asian ethnicity and material deprivation increase the risk of Epstein-Barr virus infection in childhood Hodgkin's disease. *Br J Cancer* 85, 350–6.
- Glaser SL, Gulley ML, Clarke CA *et al.* (2008) Racial/ethnic variation in EBV-positive classical Hodgkin lymphoma in California populations. *Int J Cancer* 123, 1499–507.
- Kwong YL, Anderson BO, Advani R *et al.* (2009) Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. *Lancet Oncol* 10, 1093–101.
- World Cancer Research Fund International. Cancer statistics, data on specific cancers: Stomach cancer. Available at <http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/stomach-cancer-statistics>. Accessed 8 July 2015.
- <http://www.g-i-n.net/document-store/working-groups-documents/adaptation/adapte-manual-for-guideline.pdf/view>. Accessed 8 July 2015.
- Schieir O, Hazlewood G, Akhavan P *et al.* (2010) Time to ADAPTE: a novel methodology for the development of national clinical practice guidelines to expedite dissemination [abstract]. *Ann Rheum Dis* 69 (Suppl. 3), 652.
- AGREE Collaboration (2003) Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. *Qual Saf Health Care* 12 (1), 18–23.
- Brouwers MC, Kho ME, Browman GP *et al.* (2010) AGREE II: advancing guideline development, reporting and evaluation in health care. *CMAJ* 182(18), E839–42.
- Harbour R, Miller J (2001) A new system for grading recommendations in evidence based guidelines. *BMJ* 323 (7308), 334–6.
- Smolen JS, Landewé R, Breedveld FC *et al.* (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. *Ann Rheum Dis* 73, 492–509.
- Singh JA, Furst DE, Bharat A *et al.* (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. *Arthritis Care Res (Hoboken)* 64, 625–39.

- 19 Smolen JS, Aletaha D, Bijlsma JW *et al.* (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. *Ann Rheum Dis* **69**, 631–7.
- 20 Schoels M, Smolen JS (2012) Treating rheumatoid arthritis to target: evidence-based recommendations for enhanced disease management. *Reumatol Clin* **8** (1), 1–2.
- 21 Combe B, Landewe R, Lukas C *et al.* (2007) EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). *Ann Rheum Dis* **66** (1), 34–45.
- 22 Misra R, Sharma BL, Gupta R *et al.* (2008) Indian Rheumatology Association consensus statement on the management of adults with rheumatoid arthritis. *Indian J Rheumatol* **3** (Suppl. 3), 1–16.
- 23 Mok CC, Tam LS, Chan TH *et al.* (2011) Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology. *Clin Rheumatol* **30**, 303–12.
- 24 da Mota LM, Cruz BA, Brenol CV *et al.* (2012) 2012 Brazilian Society of Rheumatology Consensus for the treatment of rheumatoid arthritis. *Rev Bras Reumatol* **52**, 152–74.
- 25 Albrecht K, Krüger K, Wollenhaupt J *et al.* (2014) German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. *Rheumatol Int* **34** (1), 1–9.
- 26 da Mota LM, Cruz BA, Brenol CV *et al.* (2013) Guidelines for the drug treatment of rheumatoid arthritis. *Rev Bras Reumatol* **53**, 158–83.
- 27 Katchamart W, Bourré-Tessier J, Donka T *et al.* (2010) Canadian recommendations for use of methotrexate in patients with rheumatoid arthritis. *J Rheumatol* **37**, 1422–30.
- 28 Bykerk VP, Akhavan P, Hazlewood GS *et al.* (2012) Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. *J Rheumatol* **39**, 1559–82.
- 29 Luqmani R, Hennell S, Estrach C *et al.* (2006) British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). *Rheumatology (Oxford)* **45**, 1167–9.
- 30 Ruyssen-Witrand A, Guernec G, Nigon D *et al.* (2014) Aiming for SDAI remission versus low disease activity at 1 year after inclusion in ESPOIR cohort is associated with better 3-year structural outcomes. *Ann Rheum Dis* **74**, 1676–83.
- 31 Buch MH, Smolen JS, Betteridge N *et al.* (2011) Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. *Ann Rheum Dis* **70**, 909–20.
- 32 The National Collaborating Centre for Chronic Conditions (2009) Rheumatoid arthritis: National clinical guidelines for management and treatment in adults. Available at <http://www.ncbi.nlm.nih.gov/pubmed-health/PMH0009576/pdf/TOC.pdf>. Accessed 8 July 2015.
- 33 Smolen JS, Schoels MM, Nishimoto N *et al.* (2013) Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. *Ann Rheum Dis* **72**, 482–92.
- 34 Fautrel B, Constantin A, Morel J *et al.* (2006) Recommendations of the French Society for Rheumatology. TNF α antagonist therapy in rheumatoid arthritis. *Joint Bone Spine* **73**, 433–41.
- 35 Fautrel B, Pham T, Mouterde G *et al.* (2007) Recommendations of the French Society for Rheumatology regarding TNF α antagonist therapy in patients with rheumatoid arthritis. *Joint Bone Spine* **74**, 627–37.
- 36 Caporali R, Conti F, Alivernini S *et al.* (2011) Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. *Clin Exp Rheumatol* **29** (3 Suppl. 66), S7–14.
- 37 Favalli EG, Caporali R, Sinigaglia L *et al.* (2011) Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety. *Clin Exp Rheumatol* **29** (3 Suppl. 66), S15–27.
- 38 Fonseca JE, Bernardes M, Canhã H *et al.* (2011) Portuguese guidelines for the use of biological agents in rheumatoid arthritis – October 2011 update. *Acta Reumatol Port* **36**, 385–8.
- 39 Deighton C, Hyrich K, Ding T *et al.* (2010) BSR and BHRP rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. *Rheumatology (Oxford)* **49**, 1197–9.
- 40 Dudler J, Finckh A, Kyburz D *et al.* (2010) Swiss consensus statement: recommendations for optimising re-treatment with MabThera (rituximab) in rheumatoid arthritis. *Swiss Med Wkly* **140**, w13073.
- 41 Pham T, Gossec L, Fautrel B *et al.* (2005) Physical examination and laboratory tests in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion. *Joint Bone Spine* **72**, 222–8.
- 42 Gossec L, Fautrel B, Pham T *et al.* (2005) Structural evaluation in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion. *Joint Bone Spine* **72**, 229–34.
- 43 Nordgaard-Lassen I, Dahlerup JF, Belard E *et al.* (2012) Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. *Dan Med J* **59** (7), C4480.
- 44 Valesini G, Montecucco C, Cutolo M (2006) Recommendations for the use of biologic (TNF-alpha blocking) agents in the treatment of rheumatoid arthritis in Italy. *Clin Exp Rheumatol* **24**, 413–23.

- 45 Mariette X, Salmon D (2003) French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. *Ann Rheum Dis* 62, 791.
- 46 Bombardier C, Hazlewood GS, Akhavan P *et al.* (2012) Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. *J Rheumatol* 39, 1583–602.
- 47 Lichauco JJ, Tankeh-Torres SA, Navarra SV *et al.* (2006) Philippine guidelines on the screening for tuberculosis prior to the use of biologic agents. *APLAR J Rheumatol* 9, 184–92.
- 48 Koike R, Harigai M, Atsumi T *et al.* (2009) Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. *Mod Rheumatol* 19, 351–7.
- 49 Miyasaka N, Takeuchi T, Eguchi K (2006) Guidelines for the proper use of etanercept in Japan. *Mod Rheumatol* 16, 63–7.
- 50 Miyasaka N, Takeuchi T, Eguchi K (2005) Official Japanese guidelines for the use of infliximab for rheumatoid arthritis. *Mod Rheumatol* 15, 4–8.
- 51 Koike R, Takeuchi T, Eguchi K *et al.* (2007) Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. *Mod Rheumatol* 17, 451–8.
- 52 Ledingham J, Deighton C British Society for Rheumatology Standards, Guidelines and Audit Working Group (2005) Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). *Rheumatology (Oxford)* 44, 157–63.
- 53 Rheumatoid Arthritis Study Group of the Portuguese Society of Rheumatology (2007) Portuguese guidelines for the use of biological agents in rheumatoid arthritis – December 2007 update. *Acta Reumatol Port* 32, 363–6.
- 54 Fonseca JE, Canhão H, Reis M *et al.* (2010) Portuguese guidelines for the use of biological agents in rheumatoid arthritis – March 2010 update. *Acta Reumatol Port* 35 (1), 95–8.
- 55 Luqmani R, Hennell S, Estrach C *et al.* (2009) British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). *Rheumatology (Oxford)* 48, 436–9.
- 56 Bukhari M, Abernethy R, Deighton C *et al.* (2011) BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. *Rheumatology (Oxford)* 50, 2311–3.
- 57 Cardiel MH, PANLAR group, GLADAR group (2006) First Latin American position paper on the pharmacological treatment of rheumatoid arthritis. *Rheumatology (Oxford)* 45(Suppl.2), ii7–22.
- 58 Smolen JS, Keystone EC, Emery P *et al.* (2007) Consensus statement on the use of rituximab in patients with rheumatoid arthritis. *Ann Rheum Dis* 66, 143–50.
- 59 Salmon D, GTI group, AFSSAPS group (2002) Recommendations about the prevention and management of tuberculosis in patients taking infliximab. *Joint Bone Spine* 69, 170–2.
- 60 Kennedy T, McCabe C, Struthers G *et al.* (2005) BSR guidelines on standards of care for persons with rheumatoid arthritis. *Rheumatology (Oxford)* 44, 553–6.
- 61 Emery P, Breedveld FC, Dougados M *et al.* (2002) Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. *Ann Rheum Dis* 61, 290–7.
- 62 Mouterde G, Dernis E, Ruysen-Witrant A *et al.* (2010) Indications of glucocorticoids in early arthritis and rheumatoid arthritis: recommendations for clinical practice based on data from the literature and expert opinion. *Joint Bone Spine* 77, 597–603.
- 63 Gorter SL, Bijlsma JW, Cutolo M *et al.* (2010) Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. *Ann Rheum Dis* 69, 1010–4.
- 64 Sekiguchi N, Kameda H, Amano K *et al.* (2006) Efficacy and safety of bucillamine, a D-penicillamine analogue, in patients with active rheumatoid arthritis. *Mod Rheumatol* 16, 85–91.
- 65 Lu LJ, Bao CD, Dai M *et al.* (2009) Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate. *Arthritis Rheum* 61, 979–87.
- 66 Hara M, Abe T, Sugawara S *et al.* (2007) Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. *Mod Rheumatol* 17 (1), 1–9.
- 67 Kawai S, Takeuchi T, Yamamoto K *et al.* (2011) Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs—a multicenter, double-blind, parallel-group trial. *Mod Rheumatol* 21, 458–68.
- 68 Takeuchi T, Kawai S, Yamamoto K *et al.* (2014) Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3,267 Japanese patients with rheumatoid arthritis. *Mod Rheumatol* 24 (1), 8–16.
- 69 Saag KG, Teng GG, Patkar NM *et al.* (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. *Arthritis Rheum* 59, 762–84.
- 70 Visser K, Katchamart W, Loza E *et al.* (2009) Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature

- research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. *Ann Rheum Dis* 68, 1086–93.
- 71 Gaujoux-Viala C, Smolen JS, Landewé R *et al.* (2010) Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. *Ann Rheum Dis* 69, 1004–9.
 - 72 Smolen JS, Landewé R, Breedveld FC *et al.* (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. *Ann Rheum Dis* 69, 964–75.
 - 73 Katchamart W, Trudeau J, Phumethum V *et al.* (2009) Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. *Ann Rheum Dis* 68, 1105–12.
 - 74 van Vollenhoven RF, Geborek P, Forslind K *et al.* (2012) Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. *Lancet* 379 (9827), 1712–20.
 - 75 Moreland LW, O'Dell JR, Paulus HE *et al.* (2012) A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. *Arthritis Rheum* 64, 2824–35.
 - 76 O'Dell JR, Mikuls TR, Taylor TH *et al.* (2013) Therapies for active rheumatoid arthritis after methotrexate failure. *N Engl J Med* 369, 307–18.
 - 77 Scott DL, Ibrahim F, Farewell V *et al.* (2015) Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. *BMJ* 350, h1046.
 - 78 Knevel R, Schoels M, Huizinga TW *et al.* (2010) Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. *Ann Rheum Dis* 69, 987–94.
 - 79 Emery P, Reginster JY, Appelboom T *et al.* (2001) WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis. *Rheumatology (Oxford)* 40, 699–702.
 - 80 Bongartz T, Sutton AJ, Sweeting MJ *et al.* (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. *JAMA* 295, 2275–85.
 - 81 Askling J, Forde CM, Brandt L *et al.* (2007) Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. *Ann Rheum Dis* 66, 1339–44.
 - 82 Thompson AE, Rieder SW, Pope JE (2011) Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. *Arthritis Rheum* 63, 1479–85.
 - 83 Bongartz T, Warren FC, Mines D *et al.* (2009) Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. *Ann Rheum Dis* 68, 1177–83.
 - 84 Le Blay P, Mouterde G, Barnette T *et al.* (2012) Risk of malignancy including non-melanoma skin cancers with anti-tumor necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studies. *Clin Exp Rheumatol* 30, 756–64.
 - 85 Moulis G, Sommet A, Béné J *et al.* (2012) Cancer risk of anti-TNF- α at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses. *PLoS ONE* 7, e48991.
 - 86 Verstappen SM, King Y, Watson KD *et al.* (2011) Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the BSR Biologics Register. *Ann Rheum Dis* 70, 823–6.
 - 87 Chung ES, Packer M, Lo KH *et al.* (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. *Circulation* 107, 3133–40.
 - 88 Listing J, Strangfeld A, Kekow J *et al.* (2008) Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? *Arthritis Rheum* 58, 667–77.
 - 89 Westlake SL, Colebatch AN, Baird J *et al.* (2011) Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. *Rheumatology* 50, 518–31.
 - 90 British Thoracic Society Standards of Care Committee (2005) BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. *Thorax* 60, 800–5.
 - 91 Caporali R, Caprioli M, Bobbio-Pallavicini F *et al.* (2008) DMARDS and infections in rheumatoid arthritis. *Autoimmun Rev* 8, 139–43.
 - 92 Doran MF, Crowson CS, Pond GR *et al.* (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. *Arthritis Rheum* 46, 2287–93.

- 93 Weinblatt ME, Keystone EC, Furst DE *et al.* (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. *Arthritis Rheum* 48 (1), 35–45.
- 94 Lipsky PE, van der Heijde DM, St Clair EW *et al.* (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. *N Engl J Med* 343, 1594–602.
- 95 Breedveld FC, Weisman MH, Kavanaugh AF *et al.* (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. *Arthritis Rheum* 54 (1), 26–37.
- 96 Keystone EC, Kavanaugh AF, Sharp JT *et al.* (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. *Arthritis Rheum* 50, 1400–11.
- 97 Westhovens R, Yocum D, Han J *et al.* (2006) The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. *Arthritis Rheum* 54, 1075–86.
- 98 Østensen M, Andreoli L, Brucato A *et al.* (2014) State of the Art: reproduction and Pregnancy in Rheumatic Diseases. *Autoimmun Rev* 14, 376–86.
- 99 Elkayam O, Caspi D, Reitblatt T *et al.* (2004) The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. *Semin Arthritis Rheum* 33, 283–8.
- 100 Fleischmann R, Kremer J, Cush J *et al.* (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. *N Engl J Med* 367, 495–507.
- 101 Kremer J, Li ZG, Hall S *et al.* (2013) Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. *Ann Intern Med* 159, 253–61.
- 102 van der Heijde D, Tanaka Y, Fleischmann R *et al.* (2013) Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. *Arthritis Rheum* 65, 559–70.
- 103 van Vollenhoven RF, Fleischmann R, Cohen S *et al.* (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. *N Engl J Med* 367, 508–19.
- 104 Burmester GR, Blanco R, Charles-Schoeman C *et al.* (2013) Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. *Lancet* 381 (9865), 451–60.
- 105 <http://www.unescap.org/stat/data/syb2011/I-People/Population.pdf>. Accessed 8 July 2015.
- 106 Lau CS, Feng PH (2007) Rheumatology without borders. *Nat Clin Pract Rheumatol* 3, 305.